Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma

Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma

Abstract Background Pancreatic adenocarcinoma (PDAC) ranks as the fourth leading cause for cancer-related deaths worldwide. N6-methyladenosine (m6A) and long non-coding RNAs (lncRNAs) are closely related with poor prognosis and immunotherapeutic effect in PDAC. The aim of this study is to construct...

Full description

Bibliographic Details
Main Authors: Xia-Qing Li, Shi-Qi Yin, Lin Chen, Aziguli Tulamaiti, Shu-Yu Xiao, Xue-Li Zhang, Lei Shi, Xiao-Cao Miao, Yan Yang, Xin Xing
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
m6A-related lncRNAs
PDAC
Immunotherapy
Prognostic values
Online Access:https://doi.org/10.1186/s12885-024-11885-8

Internet

https://doi.org/10.1186/s12885-024-11885-8

Similar Items